Feb 10, 2025 13:01
GRCE - Grace Therapeutics, Inc. Common Stock
| Day | 1m | 10m | 60m | PreMarket | Market | AfterHours | Gap |
|---|---|---|---|---|---|---|---|
| 3.0 0.11 (3.77%) | --- | --- | --- | 0.0 (0.0%) | 0.12 (4.11%) | --- | 0.0 (0.0%) |
Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage. Other products are GTx-102 Ataxia-Telangiectasia, GTx-101 Postherpetic Neuralgia, and GTx-201.
Category:
PHARMACEUTICAL PREPARATIONS
Market Period:
Closed
Earnings & Ratios
- Basic EPS:
- -0.21
- Diluted EPS:
- -0.21
- Basic P/E:
- -14.8238
- Diluted P/E:
- -14.8238
- RSI(14) 1m:
- 52.24
- VWAP:
- 3.13
- RVol:
Events
| Period | Kind | Movement | Occurred At |
|---|